677306-38-6

Usage

Uses

1H-Indazole-4-Carboxylic Acid is used as a chemical intermediate for the synthesis of various complex chemical compounds and drugs. Its role in the synthesis process is crucial, as it can be transformed into a wide range of products with different applications across different industries.
Used in Pharmaceutical Industry:
1H-Indazole-4-Carboxylic Acid is used as a building block in the development of new pharmaceuticals, contributing to the creation of innovative treatments and therapies. Its versatility in chemical reactions allows for the exploration of potential drug candidates with improved efficacy and reduced side effects.
Used in Chemical Research:
In the field of chemical research, 1H-Indazole-4-Carboxylic Acid is used as a model compound to study the properties and reactivity of indazole-based compounds. This research can lead to a better understanding of the underlying chemical mechanisms and the development of new synthetic strategies.
Used in Material Science:
1H-Indazole-4-Carboxylic Acid may also be used in material science applications, where its unique structural features can be exploited to design and develop new materials with specific properties, such as improved conductivity, stability, or optical characteristics.

InChI:InChI=1/C8H6N2O2/c11-8(12)5-2-1-3-7-6(5)4-9-10-7/h1-4H,(H,9,10)(H,11,12)

Upstream product

• 192945-49-6 1H-indazole-4-carboxylic acid methyl ester 
• 598-30-1 sec.-butyllithium 
• 18583-89-6 methyl 3-amino-2-methylbenzoate 
• 2258-42-6 formyl acetic anhydride 
• 186407-74-9 4-bromoindazole 

Downstream Products

• 1044586-92-6 N-[(4R)-6-(4-chlorophenyl)-7-(2,4-dichlorophenyl)-2,2-dimethyl-3,4-dihydro-2H-pyrano[2,3-b]pyridine-4-yl]-1H-indazole-4-carboxamide 
• 1194019-76-5 1-(4-fluoro-phenyl)-1H-indazole-4-carboxylic acid 
• 1194018-05-7 1-(4-fluoro-phenyl)-1H-indazole-4-carboxylic acid (pyridin-4-ylmethyl)-amide 
• 1194018-04-6 1-(4-fluoro-phenyl)-1H-indazole-4-carboxylic acid (pyridin-3-ylmethyl)-amide 
• 1194018-03-5 1-(4-fluoro-phenyl)-1H-indazole-4-carboxylic acid (pyridin-2-ylmethyl)-amide 
• 1194017-89-4 1-(4-fluoro-phenyl)-1H-indazole-4-carboxylic acid 4-(4-methyl-piperazine-1-sulfonyl)-benzylamide 
• 1194017-81-6 1-(4-fluoro-phenyl)-1H-indazole-4-carboxylic acid 4-dimethylsulfamoyl-benzylamide 
• 1194017-82-7 1-(4-fluoro-phenyl)-1H-indazole-4-carboxylic acid 4-isopropylsulfamoyl-benzylamide 
• 1194018-16-0 4-(methylsulfonyl)-benzyl 
• 1194018-55-7 1-(4-fluoro-phenyl)-1H-indazole-4-carboxylic acid 3-dimethylsulfamoyl-benzylamide 
• 1194017-97-4 1-(4-fluoro-phenyl)-1H-indazole-4-carboxylic acid 3-isopropylsulfamoyl-benzylamide 
• 1194017-96-3 1-(4-fluoro-phenyl)-1H-indazole-4-carboxylic acid 3-ethylsulfamoyl-benzylamide 
• 1194018-54-6 1-(4-fluoro-phenyl)-1H-indazole-4-carboxylic acid 3-methylsulfamoyl-benzylamide 
• 1194018-21-7 1-(4-fluoro-phenyl)-1H-indazole-4-carboxylic acid 3-methanesulfonyl-benzylamide 

Relevant academic research and scientific papers

Cleavage of Carboxylic Esters by Aluminum and Iodine

A one-pot procedure for deprotecting carboxylic esters under nonhydrolytic conditions is described. Typical alkyl carboxylates are readily deblocked to the carboxylic acids by the action of aluminum powder and iodine in anhydrous acetonitrile. Cleavage of lactones affords the corresponding ω-iodoalkylcarboxylic acids. Aryl acetylates undergo deacetylation with the participation of the neighboring group. This method enables the selective cleavage of alkyl carboxylic esters in the presence of aryl esters.

INDAZOLE DERIVATIVES AS ADENOSINE MONOPHOSPHATE DEAMINASE (AMPD) INHIBITORS FOR USE IN DIABETES AND RELATED DISEASES OF METABOLIC SYNDROME

Herein, we describe a method for treatment of diabetes and other disorders classified as Metabolic Syndrome. The invention provides novel AMP Deaminase (AMPD) inhibitors comprising novel indazole and benzotriazole derivatives including a phosphorous containing derivative, a carboxylic acid, or an amino acid ester prodrug. The invention also provides support for a novel mechanism of action for the existing drug metformin: direct inhibition of the enzyme AMPD. The inhibition of AMPD in turn activates AMP Kinase, known to be linked to the action of metformin. The invention also makes novel use of a double inhibitor assay allowing identification of selective AMPD inhibitors over ADA inhibitors. The new inhibitors, structurally distinct from metformin, offer selectivity that may obviate side effects known for metformin itself, providing new benefits for diabetes and Metabolic Syndrome.

Heteroaryl hydroxycarbonylation: An efficient, robust, practically scalable approach using formyl acetate as the co source

A simple, efficient, regioselective, and scalable palladium-catalyzed hydroxycarbonylation of heteroaryl halides to corresponding carboxylic acids using acetic-formic anhydride in presence of Pd(OAc)2, dppf, and diisopropylethyl amine in dimethyl formamide at 80-90 °C in excellent yields. Taylor & Francis Group, LLC.

1H-INDAZOLES, BENZOTHIAZOLES, 1,2-BENZOISOXAZOLES, 1,2-BENZOISOTHIAZOLES, AND CHROMONES AND PREPARATION AND USES THEREOF

The present invention relates generally to the field of ligands for nicotinic acetylcholine receptors (nAChR), activation of nAChRs, and the treatment of disease conditions associated with defective or malfunctioning nicotinic acetylcholine receptors, especially of the brain. Further, this invention relates to novel compounds (indazoles and benzothiazoles), which act as ligands for the α7 nAChR subtype, methods of preparing such compounds, compositions containing such compounds, and methods of use thereof.

HETEROAROMATIC UREAS WHICH MODULATE THE FUNCTION OF THE VANILLOID-1 RECEPTOR (VR1)

Compounds of formula (I): are useful as therapeutic compounds, particularly in the treatment of pain and other conditions ameliorated by the modulation of the function of the vanilloid-1 receptor (VR1).

INDAZOLES, BENZOTHIAZOLES, AND BENZOISOTHIAZOLES, AND PREPARATION AND USES THEREOF

The present invention relates generally to the field of ligands for nicotinic acetylcholine receptors (nAChR), activation of nAChRs, and the treatment of disease conditions associated with defective or malfunctioning nicotinic acetylcholine receptors, especially of the brain. Further, this invention relates to novel compounds (indazoles and benzothiazoles), which act as ligands for the α7 nAChR subtype, methods of preparing such compounds, compositions containing such compounds, and methods of use thereof.